Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Uploaded on Jul 1, 2010
Jul 1, 2010 -- GlaxoSmithkline (GSK) is lower after the drug giant said it had amended a licensing agreement with Denmark's Genmab for their Arzerra cancer drug in a way that will have a "material impact" on Genmab's 2010 prospects, Reuters reports.
GlaxoSmithKline shares are down $0.22, or 0.65%, to $33.